[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Monoclonal Antibodies in Cancer Treatment Discussed in Topic RNCOS Report Available at MarketPublishers.com

18 Sep 2013 • by Natalie Aster

LONDON – Due to the rapid growth in the number of cancer patients, pharmaceutical companies have stepped up investment into oncology studies with a focus on monoclonal antibodies (mAbs) – laboratory-produced molecules made to attach to specific defects in cancer cells. In 2012, about 13 million people were affected by cancer. By 2020, the number of patients diagnosed with cancer is expected to reach 17 million.

Various cancer mAbs are already available in the market, and there also those that are currently under discovery or development. That majority of the mAbs in the pipeline are in phase III trials with most of them devoted to solid tumour, lung cancer, breast cancer, and NHL. The approval of these drugs will drive a major change in the market in terms of market share of current drugs. Currently assessed at USD 24 billion, the cancer monoclonal antibodies market is expected to be worth nearly USD 34 billion by end-2017.

Topical report “Cancer Monoclonal Antibodies Market Forecast to 2017” developed by RNCOS provides a comprehensive analysis of the cancer monoclonal antibodies market. The study includes valuable information on the key trends and drivers of the market, market size and share. It offers an in-depth overview of the global burden of cancer, with breakdowns of incidences by type and geography. A detailed overview of monoclonal technology enables to understand the various types of antibodies and the diverse types of cancer therapies which use mAbs. The research profiles every anti-cancer monoclonal antibody available in the market, estimating the current and future market of the five of them. The report is supplemented with a competitive analysis of the leading mAb players, with brief descriptions of every player along with a list of current and pipeline mAbs.

Report Details:

Cancer Monoclonal Antibodies Market Forecast to 2017
Published: August, 2013
Pages: 105
Price: US$ 1,500.00

Other In-demand Studies by RNCOS Include:

More market research reports by the publisher can be found at RNCOS page.


The Market Publishers, Ltd.
Tanya Levdikova
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected]

Analytics & News

Weekly Digest